Laboratorio Reig Jofre : 2018 06 21 - Reig Jofre informs on the start of coverage through three equity research reports (PDF)

CNMV Edison, 4 28006 Madrid

Barcelona (Spain), June 21, 2018

RELEVANT FACT

Dear Sir,

In accordance with the Article 228 of Royal Legislative Decree 4/2015, dated 23 October, which enacts the consolidated text of the Securities Market Act, LABORATORIO REIG JOFRE SA ("Reig Jofre" or "the Company") submits hereafter press release on the start of coverage through three equity research reports.

Adolf Rousaud

Secretary of the Board of Directors Laboratorio Reig Jofre SA

REIG JOFRE ANNOUNCES THE START OF COVERAGE THROUGH THREE EQUITY RESEARCH REPORTS

• • To provide investors a better knowledge of the company, the sector in which it operates and the capital markets, Reig Jofre informs on the start of coverage through three advisory reports on RJF expected return and a detailed analysis of the company

Barcelona (Spain), June 21, 2018. The pharmaceutical company Reig Jofre announces the start of coverage of its RJF value through three equity research reports by three renowned equity research firms.

Intermoney Valores SV is the Investment Services arm of the CIMD Group, specialized in providing institutional and professional clients the access to fixed income and equity markets. Intermoney Valores issued an independent (non-sponsored) research with the recommendation to buy and established the target price of € 3.3 per share.

Solventis, an independent financial group founded by a team of professionals with backgrounds in different areas of the investment banking sector, issued a sponsored research with a target price of € 3.15 per share.

Bankinter Securities, the bank's securities firm, established the target price per share at € 3.30 in its sponsored research. Bankinter Securities offer its partners and institutional investors access to a wide financial services range, both domestically and internationally.

The equity research reports issued by Solventis (Spanish version) and Bankinter (English version) are available on the investors section of the Company's website:http://www.reigjofre.com/en/investors/analysts-covering-the-stock

Receive Reig Jofre's news by registering in the company's subscription center of the new corporate website:www.reigjofre.com

About Reig Jofre

Founded in 1929 in Barcelona, Reig Jofre is a pharmaceutical company focused on the research, development, manufacture and marketing of pharmaceutical products and nutritional supplements. Reig Jofre directs its R&D to the development of new formulations and indications in the therapeutic areas of (dermatology, respiratory/ENT, gynecology); to the development of innovative molecules in collaboration with research start-ups or knowledge centers in either the technological specialization areas of (injectable products and beta-lactam antibiotics) or the therapeutic areas; and to the development of generic medicines of technological specialization. Reig Jofre has over 900 employees, 4 development and manufacturing centers in Europe (2 in Toledo, 1 in Barcelona and 1 in Sweden), direct sales in 7 countries and over 130 commercial partners in 67 countries worldwide. The company reached sales of €168 M in 2017. Reig Jofre trades on the Spanish stock exchange under the ticker RJF. Total outstanding shares: 64,153,178 shares.

For further information

Media

Inma Santa-Pau

Tel. (+34) 93 480 67 10 - ext. 1242 │inma.santapau@reigjofre.com

Shareholder office

Patricia Casado

Tel. (+34) 93 480 67 10 - ext. 1237 │patricia.casado@reigjofre.com

2